EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Richard Lafayette, Sean J Barbour, Robert M Brenner, Kirk N Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Vivekanand Jha, Beom Seok Kim iD, Adrian Liew, Bart Maes, Atanu Pal und 10 weitere

New England Journal of Medicine · 12.02.2026 · 394 (7) · 647-657

DOI: 10.1056/nejmoa2510198 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.02.2026. Verfasst von Richard Lafayette und 21 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Creatinine, Glomerulonephritis, IGA, Proteinuria, Recombinant Fusion Proteins. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Vera Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CreatinineGlomerulonephritis, IGAProteinuriaRecombinant Fusion ProteinsAdultFemaleHumansMaleMiddle AgedB-Cell Activating FactorDouble-Blind MethodInjections, SubcutaneousTransmembrane Activator and CAML Interactor ProteinTumor Necrosis Factor Ligand Superfamily Member 13Treatment Outcome

Substanzen

B-Cell Activating FactorCreatinineRecombinant Fusion ProteinsTACI receptor-IgG Fc fragment fusion proteinTNFSF13B protein, humanTransmembrane Activator and CAML Interactor ProteinTumor Necrosis Factor Ligand Superfamily Member 13

Autor:innen und Institutionen

  • Stanford University, Stanford, CA.
  • Division of Nephrology, University of British Columbia, Vancouver, Canada.
  • Vera Therapeutics, Brisbane, CA.
  • University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Faculty of Medicine, Division of Nephrology, Kocaeli University, Kocaeli, Turkey.
  • Departments of Nephrology and Cardiology, RWTH Aachen University Hospital, Aachen, Germany.

ORCID-Profile: Beom Seok Kim

Förderung

  • Vera Therapeutics, Inc.

Zitieren

APA

Lafayette, R., Barbour, S. J., Brenner, R. M., Campbell, K. N., Doan, T., Eren, N., Floege, J., Jha, V., Kim, B. S., Liew, A., Maes, B., Pal, A., Pecoits-Filho, R., Phoon, R. K. S., Rizk, D. V., Suzuki, H., Tesař, V., Trimarchi, H., Wei, X., …, & ORIGIN Phase 3 Trial Investigators (2026). A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. New England Journal of Medicine, 394(7), 647-657. https://doi.org/10.1056/nejmoa2510198

Vancouver

Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, et al. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. New England Journal of Medicine. 2026;394(7):647-657. doi:10.1056/nejmoa2510198

BibTeX
@article{Lafayette2026,
  author = {Lafayette, Richard and Barbour, Sean J and Brenner, Robert M and Campbell, Kirk N and Doan, Tom and Eren, Necmi and Floege, Jürgen and Jha, Vivekanand and Kim, Beom Seok and Liew, Adrian and Maes, Bart and Pal, Atanu and Pecoits-Filho, Roberto and Phoon, Richard K S and Rizk, Dana V and Suzuki, Hitoshi and Tesař, Vladimir and Trimarchi, Hernán and Wei, Xuelian and Zhang, Hong and Barratt, Jonathan and ORIGIN Phase 3 Trial Investigators, ORIGIN Phase 3 Trial Investigators},
  title = {A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {7},
  pages = {647--657},
  doi = {10.1056/nejmoa2510198}
}
Kostenlos starten →